Levetiracetam: the first SV2A ligand for the treatment of epilepsy
- PMID: 23484603
- DOI: 10.1517/17460441.2.11.1537
Levetiracetam: the first SV2A ligand for the treatment of epilepsy
Abstract
Levetiracetam is a multiple action drug that primarily acts through an interaction with the synaptic vesicle protein 2A. Levetiracetam is the first drug of its kind to be approved for the treatment of epilepsy and is now the most prescribed among the newer antiepileptic drugs. The discovery process identifying levetiracetam's antiepileptic potential was unique because it challenged several dogmas of antiepileptic drug discovery, and thereby encountered skepticism from the epilepsy community. This was contrasted by a very successful development programme leading to rapid regulatory approval by the FDA. The history of levetiracetam proves that a small core group of committed scientists and physicians, who dare to challenge the conventional scientific doctrine, can be successful in bringing to market a truly novel therapy for epilepsy patients.
Similar articles
-
[Newer antiepileptic drugs].Brain Nerve. 2007 Feb;59(2):147-56. Brain Nerve. 2007. PMID: 17380779 Review. Japanese.
-
Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.Epilepsia. 2009 Mar;50(3):422-33. doi: 10.1111/j.1528-1167.2008.01727.x. Epub 2008 Aug 19. Epilepsia. 2009. PMID: 18717715
-
Levetiracetam in the treatment of idiopathic generalized epilepsies.Epilepsia. 2005;46 Suppl 9:154-60. doi: 10.1111/j.1528-1167.2005.00329.x. Epilepsia. 2005. PMID: 16302890
-
Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.Epilepsia. 2009 Jul;50(7):1729-40. doi: 10.1111/j.1528-1167.2009.02089.x. Epub 2009 Apr 19. Epilepsia. 2009. PMID: 19486357
-
Mechanisms of action of antiepileptic drugs: the search for synergy.Curr Opin Neurol. 2010 Apr;23(2):157-63. doi: 10.1097/WCO.0b013e32833735b5. Curr Opin Neurol. 2010. PMID: 20125013 Review.
Cited by
-
Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.Neurosci Bull. 2024 May;40(5):594-608. doi: 10.1007/s12264-023-01138-2. Epub 2023 Oct 28. Neurosci Bull. 2024. PMID: 37897555 Free PMC article. Review.
-
The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?Neurochem Res. 2017 Jul;42(7):1926-1938. doi: 10.1007/s11064-016-2025-7. Epub 2016 Aug 8. Neurochem Res. 2017. PMID: 27502939 Review.
-
Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.Br J Pharmacol. 2008 Aug;154(8):1662-71. doi: 10.1038/bjp.2008.198. Epub 2008 May 26. Br J Pharmacol. 2008. PMID: 18500360 Free PMC article.
-
Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience.Ther Adv Neurol Disord. 2019 Sep 9;12:1756286419873518. doi: 10.1177/1756286419873518. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 31523280 Free PMC article. Review.
-
Mechanisms of levetiracetam in the control of status epilepticus and epilepsy.Front Neurol. 2014 Jan 31;5:11. doi: 10.3389/fneur.2014.00011. eCollection 2014. Front Neurol. 2014. PMID: 24550884 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
